| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $31,454,327 ) (Continued on the next page) |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | RF1AG081286 | Default mode network dysfunction in Down Syndrome | 001 | 1 | NIH | 4/6/2023 | -$1,844,755 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | RF1AG081286 | Default mode network dysfunction in Down Syndrome | 000 | 1 | NIH | 4/3/2023 | $1,844,755 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 000 | 3 | NIH | 8/2/2023 | $664,584 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS131689 | A Single Cell and Proteomic Precision Medicine Approach to Glyburide Responsive Contusion Expansion in Severe Traumatic Brain Injury | 000 | 1 | NIH | 4/4/2023 | $251,954 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS120331 | Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | 000 | 3 | NIH | 8/2/2023 | $140,970 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG073212 | Repurposing Siponimod for Alzheimer's Disease | 003 | 3 | NIH | 8/17/2023 | $687,290 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 011 | 5 | NIH | 8/24/2023 | $701,731 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS115815 | A Translational Evaluation of Sur1-Trpm4 Imaging Endophenotypes and Genetics to Direct Precision Medicine for Cerebral Edema After Traumatic Brain Injury | 000 | 3 | NIH | 5/1/2023 | $557,724 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01ES021488 | Imaging Biomarkers of Neurotoxicity in Welders | 005 | 9 | NIH | 6/6/2023 | $507,244 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01HL156891 | Chronic Lung Allograft Dysfunction: Role for Tumor Suppressor LKB1 in Exosomes | 000 | 2 | NIH | 6/23/2023 | $410,524 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | P01AG014449 | Neurobiology of Mild Cognitive Impairment in the Elderly | 002 | 25 | NIH | 5/17/2023 | $2,396,025 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 001 | 4 | NIH | 1/31/2023 | $38,732 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS109584 | Mechanisms for intracranial aneurysm rupture | 000 | 4 | NIH | 12/2/2022 | $348,598 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01NS109382 | EGF-ADAM17 axis in the pathophysiology of intracranial aneurysm | 000 | 5 | NIH | 8/17/2023 | $439,103 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R21NS125535 | Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI | 002 | 2 | NIH | 8/2/2023 | $198,494 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01ES029524 | NOVEL PET MARKERS OF COGNITIVE IMPAIRMENT IN MANGANESENEUROTOXICITY | 001 | 5 | NIH | 6/9/2023 | $475,542 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 000 | 2 | NIH | 11/9/2022 | $359,442 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01NS124575 | Multi-scale functional connectivity in preclinical models of Parkinson's disease | 001 | 2 | NIH | 1/31/2023 | $39,938 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 00 | 26 | HRSA | 3/22/2023 | $754,341 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | OT2NS136939 | Access for All in ALS (ALL ALS) West Clinical Coordinating Center | 000 | 1 | NIH | 9/22/2023 | $16,733,501 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG077780 | Roles of aging and cellular senescence in the development of intracranial aneurysm rupture | 000 | 1 | NIH | 5/19/2023 | $608,992 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R61NS127268 | Diffusion MRI Biomarkers of Peripheral Nerve Trauma | 000 | 1 | NIH | 4/21/2023 | $824,668 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | F32DK130535 | Circadian Regulation of the Dorsomedial Hypothalamic Nucleus and Its Impact on Energy Homeostasis | 000 | 2 | NIH | 11/29/2022 | $67,582 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | RF1AG081286 | Default mode network dysfunction in Down Syndrome | 002 | 1 | NIH | 4/13/2023 | $1,844,755 |
| | 2023 | 2023 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | F32DK130535 | Circadian Regulation of the Dorsomedial Hypothalamic Nucleus and Its Impact on Energy Homeostasis | 001 | 2 | NIH | 3/7/2023 | $1,918 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 010 | 4 | NIH | 7/31/2023 | $1,022,207 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG073212 | Repurposing Siponimod for Alzheimer's Disease | 000 | 2 | NIH | 11/23/2022 | $0 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG073212 | Repurposing Siponimod for Alzheimer's Disease | 002 | 2 | NIH | 2/3/2023 | $731,856 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01ES021488 | Imaging Biomarkers of Neurotoxicity in Welders | 001 | 8 | NIH | 2/10/2023 | $526,094 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 009 | 4 | NIH | 4/7/2023 | $0 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 007 | 4 | NIH | 3/28/2023 | -$402,379 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01ES021488 | Imaging Biomarkers of Neurotoxicity in Welders | 004 | 8 | NIH | 5/18/2023 | $572,063 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 007 | 4 | NIH | 3/28/2023 | -$1,022,207 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 003 | 4 | NIH | 2/3/2023 | $402,379 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 003 | 4 | NIH | 2/3/2023 | $1,022,207 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS125535 | Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI | 001 | 1 | NIH | 6/9/2023 | $223,494 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS125535 | Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI | 000 | 1 | NIH | 5/29/2023 | -$223,494 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R61NS119642 | Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS | 000 | 1 | NIH | 9/21/2023 | $0 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 002 | 1 | NIH | 7/10/2023 | -$615,958 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 000 | 1 | NIH | 6/14/2023 | $0 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R21NS125861 | Astrocyte regulation of cortical neurodegeneration in C9orf72 FTD/ALS | 000 | 1 | NIH | 4/10/2023 | $0 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | R01CA213158 | Establishing the Validity of Brain Tumor Perfusion Imaging | 001 | 6 | NIH | 7/4/2023 | $0 |
| | 2023 | 2022 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01AG059008 | MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients | 010 | 4 | NIH | 7/31/2023 | $402,379 |
| | 2023 | 2021 | Dignity Health | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | 1P1CMS331609 | Accountable Health Communities, Track 3Dignity SJHMC 2MATCH Project | 03 | 5 | CMS | 12/1/2022 | -$293,771 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | UG3CA247606 | Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer | 001 | 2 | NIH | 8/18/2023 | $0 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 BERRY ST STE 300 | SAN FRANCISCO | CA | 94107-1773 | SAN FRANCISCO | USA | UG3CA247606 | Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer | 000 | 2 | NIH | 12/7/2022 | $0 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 01 | 24 | HRSA | 3/14/2023 | -$78,516 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 Berry St Ste 300 | San Francisco | CA | 94107-1773 | SAN FRANCISCO | USA | H7600510 | Ryan White Part C Outpatient EIS Program | 00 | 26 | HRSA | 3/22/2023 | $68,544 |
| | 2023 | 2021 | DIGNITY HEALTH | 185 BERRY ST STE 200 | SAN FRANCISCO | CA | 94107-1777 | SAN FRANCISCO | USA | R01DA043567 | Prototoxin Effects on Nicotinic Receptor Function | 000 | 4 | NIH | 2/28/2023 | -$333,038 |
|
